Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016

BACKGROUND: New hepatitis C virus (HCV) drugs—direct-acting antivirals (DAAs)—are highly effective but costly, which raises a concern about limited access to DAAs by vulnerable populations. Previous studies of disparities in DAA use across patient groups showed mixed results, but their generalizabil...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Manag Care Spec Pharm
Autores principales: Jung, Jeah, Du, Ping, Feldman, Roger, Kong, Lan, Riley, Thomas
Formato: Artigo
Lenguaje:Inglês
Publicado: Academy of Managed Care Pharmacy 2019
Materias:
Research Brief
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6823635/
https://ncbi.nlm.nih.gov/pubmed/31663464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2019.25.11.1236
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares